文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

心脏骤停后VA-ECMO救援治疗的生存与结局

Survival and Outcomes After Cardiac Arrest With VA-ECMO Rescue Therapy.
PubMed 文献 · Shock · 2021-01-01
一句话结论单中心回顾性研究显示,心脏骤停接受ECMO救援治疗者院内生存率38.2%,mSAVE评分与BMI可预测生存和良好神经结局。

该单中心回顾性研究纳入2011年至2019年89例心脏骤停并接受心肺复苏及救援ECMO支持的患者,评估生存、非神经及神经结局,并验证SAVE与改良SAVE(mSAVE)评分对生存和良好神经结局的预测价值。结果显示院内生存率38.2%,中位CPC评分为2;生存者BMI更低、肥胖更少、CPR时间更短、气管切开更多、肾脏替代治疗(RRT)更少。mSAVE评分可预测院内生存(OR 1.11;95%CI 1.03-1.19;P=0.004)和良好神经结局(OR 1.11;95%CI 1.03-1.20;P=0.009)。多因素分析中,mSAVE、BMI、CPR时间、气管切开和RRT与院内生存相关(c-statistic 0.864),mSAVE和BMI与良好神经结局相关(c-statistic 0.805)。

要点

  • 89例心脏骤停接受ECMO救援治疗患者,院内生存率38.2%,中位CPC评分2。
  • 生存者较非生存者BMI更低(27.9±4.2 vs 32.3±7.5 kg/m2,P=0.003)、肥胖更少(26.5% vs 49.1%,P=0.035)、CPR时间更短(35.5±31.7 vs 58.0±49.5分钟,P=0.019)。
  • 生存者气管切开更多(38.2% vs 7.3%,P<0.001)、RRT更少(17.6% vs 38.2%,P=0.031)。
  • mSAVE评分预测院内生存(OR 1.11;95%CI 1.03-1.19;P=0.004)和良好神经结局(OR 1.11;95%CI 1.03-1.20;P=0.009)。
  • 良好神经结局者体重更低(86.2±17.9 vs 98.1±19.4 kg,P=0.010)、BMI更低(28.1±4.5 vs 33.9±7.9 kg/m2,P<0.001)、肥胖更少(29.7% vs 56.3%,P=0.026)。

适用人群与场景

  • 2011年至2019年单中心心脏骤停并接受心肺复苏及救援ECMO支持的患者,共89例。

研究设计与关键结果

  • 单中心回顾性研究,纳入89例心脏骤停接受心肺复苏和救援ECMO支持的患者,评估生存、非神经及神经结局,并验证SAVE和mSAVE评分。
  • 院内生存率38.2%,中位CPC评分2。
  • 生存者较非生存者BMI更低(27.9±4.2 kg/m2 vs 32.3±7.5 kg/m2,P=0.003)、肥胖(BMI≥30 kg/m2)更少(26.5% vs 49.1%,P=0.035)、CPR时间更短(35.5±31.7分钟 vs 58.0±49.5分钟,P=0.019)、气管切开更多(38.2% vs 7.3%,P<0.001)、RRT更少(17.6% vs 38.2%,P=0.031)。
  • 良好神经结局者较非良好神经结局者体重更低(86.2±17.9 kg vs 98.1±19.4 kg,P=0.010)、BMI更低(28.1±4.5 kg/m2 vs 33.9±7.9 kg/m2,P<0.001)、肥胖更少(29.7% vs 56.3%,P=0.026)。
  • mSAVE评分预测院内生存(OR 1.11;95%CI 1.03-1.19;P=0.004)和良好神经结局(OR 1.11;95%CI 1.03-1.20;P=0.009)。
  • 多因素分析中,院内生存的预测因素包括mSAVE、BMI、CPR时间、气管切开和RRT(c-statistic 0.864);良好神经结局的预测因素包括mSAVE和BMI(c-statistic 0.805)。

证据类型、等级与局限

  • 单中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,mSAVE、BMI、RRT和气管切开是心脏骤停接受ECMO救援治疗患者院内生存的预测因素,mSAVE和BMI是良好神经结局的预测因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Extracorporeal membrane oxygenation (ECMO) use in patients with cardiac arrest is increasing. Utilization remains variable between centers using ECMO as a rescue therapy or early protocolized extracorporeal cardiopulmonary resuscitation.

METHODS: Single-center, retrospective evaluation of cardiac arrest with cardiopulmonary resuscitation and rescue ECMO support from 2011 through 2019. Study objectives included survival, non-neurologic, and neurologic outcomes; validation of the SAVE and modified SAVE (mSAVE) scores for survival and favorable neurologic outcome; and predictive factor identification in cardiac arrest with ECMO rescue therapy.

RESULTS: Eighty-nine patients were included. In-hospital survival was 38.2% and median CPC score was 2. Survivors had lower BMI (27.9 ± 4.2 kg/m2 vs. 32.3 ± 7.5 kg/m2, P = 0.003), less obesity (BMI ≥ 30 kg/m2) (26.5% vs. 49.1%, P = 0.035), shorter CPR duration (35.5 ± 31.7 m vs. 58.0 ± 49.5 m, P = 0.019), more tracheostomy (38.2% vs. 7.3%, P < 0.001), and less renal replacement therapy (RRT) (17.6% vs. 38.2%, P = 0.031). Patients with a favorable neurologic outcome had lower body weight (86.2 ± 17.9 kg vs. 98.1 ± 19.4 kg, P = 0.010), lower BMI (28.1 ± 4.5 kg/m2 vs. 33.9 ± 7.9 kg/m2, P < 0.001), and less obesity (29.7% vs. 56.3%, P = 0.026). mSAVE score predicted in-hospital survival (OR 1.11; 95%CI 1.03-1.19; P = 0.004) and favorable neurologic outcome (OR 1.11; 1.03-1.20; P = 0.009). Multivariate analysis for in-hospital survival included mSAVE, BMI, CPR-time, tracheostomy, and RRT (c-statistic: 0.864). Favorable neurologic outcome included mSAVE and BMI (c-statistic: 0.805).

CONCLUSIONS: mSAVE, BMI, RRT, and tracheostomy are predictors of in-hospital survival and mSAVE and BMI are predictors of favorable neurologic outcome in cardiac arrest with ECMO rescue therapy.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Schurr JW, Noubani M, Santore LA, et al. Survival and Outcomes After Cardiac Arrest With VA-ECMO Rescue Therapy. Shock. 2021. PMID: 33988538. doi:10.1097/SHK.0000000000001809

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。